Status:
COMPLETED
INST Phase II Trial of Gemcitabine and Irinotecan in Patients With Relapsed or Refractory Lymphoma.
Lead Sponsor:
University of New Mexico
Conditions:
Non-Hodgkin's Lymphoma
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Primary objectives * Assess the response rate in patients with recurrent or refractory B-cell NHL or Hodgkins disease, treated with the combination of the gemcitabine and irinotecan. Secondary objec...
Detailed Description
The purpose of the study is to see how well patients with relapsed or refractory lymphoma respond to treatment with Gemcitabine and Irinotecan. Patients on this study take part because they have relap...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with a histologic diagnosis of non-HIV related B-cell NHL or Hodgkins disease are eligible.
- Patients should have documented evidence of refractory or relapsed NHL or Hodgkins disease for inclusion.
- Patient should have received 1 or more prior chemotherapeutic regimens for relapse, and should have completed last course of treatment at least 3 weeks prior to enrollment.
- The patient must have bidimensionally measurable or evaluable disease.
- Age \> 18 years.
- ECOG Performance status \< 2
- Informed consent.
- ANC \> 1.5, platelet count \> 100K, creatinine\< 2.0, bilirubin \< 3
- Female patients must have a negative pregnancy test.
Exclusion
Key Trial Info
Start Date :
August 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2005
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT00276003
Start Date
August 1 2002
End Date
August 1 2005
Last Update
January 7 2010
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Lovelace Sandia Health Systems Dept of Hematology
Albuquerque, New Mexico, United States, 87108
2
University of New Mexico
Albuquerque, New Mexico, United States, 87131